Work

Development of novel nucleic acid technologies for tackling neurological diseases

Year: 2019
Type: dissertation
Abstract: Nucleic acid technologies such as antisense oligonucleotides (AOs) and DNAzymes can bind specifically to target messenger RNA and modulate gene expression by different mechanisms of actions.Recent approval of Nusinersen (Spinraza), by the United States Food and Drug Administration for the treatment of spinal muscular atrophy has demonstrated the potential of nucleic acid technologies in treatment of neuromuscular diseases.This thesis explores the potential of AOs and DNAzymes for tackling neurological diseases, particularly multiple sclerosis and Alzheimer's disease.Chapter 1 provides a broad overview of the various nucleic acid technologies including the importance of chemical modifications and delivery of the nucleic acid molecules for clinical applications.Chapter 2 focused on developing DNAzymes targeting integrin subunit alpha 4 (ITGA4), a validated therapeutic target in multiple sclerosis.A DNAzyme candidate, RNV143, 4.4.1.2Evaluation of the most efficient 2'-OMePS AO cocktail to induce exon 17 skipping... 4.4.1.3Evaluation of the most efficient 2'-OMePS AO cocktail to induce exon-skipping in fibroblasts......................
Institution: Murdoch University
Language: English
Open Access status: green
OpenAlex ID: W3054995059
Cites: 274
Cited by:
Related to: 10